Get the Stockscreener App
1.93
0.52%
-0.01
After Hours:
1.98
0.05
+2.59%
Alaunos Therapeutics Inc stock is traded at $1.93, with a volume of 14,353.
It is down -0.52% in the last 24 hours and down -7.21% over the past month.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
See More
Previous Close:
$1.94
Open:
$1.91
24h Volume:
14,353
Relative Volume:
0.96
Market Cap:
$4.71M
Revenue:
$3,000
Net Income/Loss:
$-4.11M
P/E Ratio:
-0.8899
EPS:
-2.1688
Net Cash Flow:
$-3.23M
1W Performance:
-4.93%
1M Performance:
-7.21%
6M Performance:
-34.58%
1Y Performance:
-31.27%
1-Day Range:
$1.8522
$1.95
1-Week Range:
$1.81
$2.19
52-Week Range:
$1.67
$4.59
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Name
Alaunos Therapeutics Inc
Sector
Industry
Phone
(346) 355-4099
Address
501 E LAS OLAS BLVD, FORT LAUDERDALE
Compare TCRT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
1.93 | 4.74M | 3,000 | -4.11M | -3.23M | -2.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Stock (TCRT) Latest News
CEO Holger Weis takes Alaunos Therapeutics, Inc. (TCRT) stock instead of salary - Stock Titan
Alaunos Therapeutics, Inc. (TCRT) director receives 8,138-share board fee grant - Stock Titan
Alaunos Therapeutics (TCRT) director gets 8,789-share equity grant in lieu of fees - Stock Titan
Alaunos Therapeutics (TCRT) director granted 8,463 shares for board fees - Stock Titan
Alaunos Therapeutics Inc (TCRT) Cash Flow - TradingKey
TradingKey - TradingKey
Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alaunos Therapeutics Inc (TCRT) Institutional Confidence - TradingKey
Alaunos Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRT - TradingView
Alaunos Therapeutics Inc (TCRT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TCRT|Alaunos Therapeutics Inc|Price:1.940|Chg%:+0.020 - TradingKey
Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alaunos Therapeutics (TCRT) Edges Higher as Stock Holds Above Key SupportMACD Signal Stocks - dars.gov.et
Price to earnings forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Price to book forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits
Enterprise value to revenue forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
Price to sales forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
MSN Money - MSN
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Stock grant to Alaunos (TCRT) CEO issued in lieu of salary - Stock Titan
Alaunos Therapeutics Inc (TCRT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TCRT Q4 2023 Earnings: Miss on EPS as Alaunos Continues Pre-Clinical DevelopmentEarnings Per Share - dars.gov.et
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver - The National Law Review
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study - markets.businessinsider.com
Alaunos Reports New Preclinical Liver Data for ALN1003 - TipRanks
Alaunos Therapeutics (TCRT) posts new ALN1003 mouse liver and metabolic findings - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market SessionUniverse Pharmaceuticals (NASDAQ:UPC), Deco - Benzinga
Alaunos Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRT) - TradingView
TCRT Q4 2023 Earnings: EPS Misses Estimates Amid Ongoing Clinical DevelopmentEstimate Dispersion - dars.gov.et
Alaunos Therapeutics Inc (TCRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alaunos Therapeutics (TCRT) CEO takes 7,761-share stock grant in lieu of salary - Stock Titan
TCRT Q4 2023 Earnings: EPS Miss Reflects Clinical-Stage Operational HeadwindsNew Analyst Coverage - dars.gov.et
Alaunos Therapeutics Inc (TCRT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alaunos Therapeutics Inc (TCRT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alaunos Therapeutics Inc (TCRT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TCRT Q4 2023 Earnings: EPS Miss Amid Ongoing Clinical DevelopmentEarnings Surprise Report - newsline.com
Number of shareholders of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
TCRT Q4 2023 Earnings: EPS Misses Estimates, No Revenue Reported, Stock DeclinesEarnings Stability Report - newsline.com
Alaunos Therapeutics (TCRT) Declines 6.56% as Stock Tests Key Support Near $2.17Swing Trade Setups - newsline.com
TCRT Q4 2023 Earnings: Wider-Than-Expected Loss on Lack of RevenueEstimate Dispersion - dars.gov.et
Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk - Bez Kabli
Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology
Alaunos Therapeutics (TCRT) Declines 4.18% as Biotech Sector Pressure Tests Key Support LevelsQuality ETF - newsline.com
TCRT Q4 2023 Earnings: EPS Misses Estimates Amid Continued Clinical-Stage Cash BurnGuidance Update - dars.gov.et
Alaunos Therapeutics Q4 2023 Earnings: EPS Miss Widens as Pre-Revenue Biotech Faces Continued Headwinds - DonanımHaber
Alaunos Therapeutics (TCRT) Dips 6.86% as Stock Approaches Critical Support LevelChaikin Flow - The Legal Advocate
TCRT Q4 2023 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Season Outlook - newsline.com
TCRT Q4 2023 Earnings: Loss Wider Than Estimates but Stock ClimbsGuidance Accuracy Score - dars.gov.et
Alaunos Therapeutics (TCRT) CEO takes 3,700 shares instead of salary - Stock Titan
Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers - MSN
Alaunos Therapeutics Inc Stock (TCRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):